← Leaderboards
Aniket A Kawatkar
Kaiser Foundation Research Institute
$3,696,730
Attributed
$3,888,105
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,888,105 · 3
By mechanism
R01$2,695,216 · 1
R56$810,138 · 1
R21$382,751 · 1
Top collaborators
- Kim N Danforth2 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Marilyn L Kwan$12,106,221
- Lawrence H Kushi$60,993,337
- Carmit Kurn McMullen$5,401,038
- Charles D Moore$889,646
- Song Yao$11,329,919
Others in their field
Other Emerging Leaders on “Prevent”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$141,293,697
- Kimberly Smith · Ppd Development Lp$115,671,664
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$112,282,390
- Beth Baseler · Leidos Biomedical Research, Inc.$100,071,064
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
Research focus
PreventDecision MakingCancer RecurrenceMortalityRecurrenceFutureOncologistNeoplasm RegistryTumorMalignant NeoplasmsCancer PatientRisk StratificationOutcome StudyInnovationAmericanAtherosclerosisCardiotoxicityClinical PracticeCardiovascular DiseasesCollegeComputerized Medical RecordCardiovascular SystemCancer SurvivorCancer Therapy
Grant awards (7)
Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes$633,608
R01 · FY2025 · HL · contact PI
Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes$674,452
R01 · FY2024 · HL · contact PI
Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes$668,794
R01 · FY2023 · HL · contact PI
Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes$718,362
R01 · FY2022 · HL · contact PI
Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes$810,138
R56 · FY2020 · HL · contact PI
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research$210,481
R21 · FY2020 · CA · contact PI
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research$172,270
R21 · FY2019 · CA · contact PI